Table 2.
Baseline characteristics of patients enrolled in observational studies on left atrial appendage occlusion that reported observed versus expected bleeding events
| Baseline characteristics | n (%), Mean ± SD |
|---|---|
| Total number of studies | 26 |
| Total number of patients | 10,056 |
| Age (years) | 74.0 ± 8.7 |
| Men | 6,029 (60%) |
| Type of atrial fibrillation | |
| Paroxysmal | 1,495 (15%) |
| Nonparoxysmal | 8,561 (85%) |
| Hypertension | 6,825 (68%) |
| Diabetes mellitus | 2,397 (24%) |
| Prior stroke/transient ischemic attack | 3,135 (31%) |
| Peripheral vascular disease | 868 (9%) |
| Congestive heart failure | 1,628(16%) |
| Mean CHA2DS2-VASc Score | 4.21±1.48 |
| Mean HASBLED Score | 3.08±1.14 |
| Left appendage occlusion device | |
| Watchman | 4,634 (46%) |
| Amplatzer cardiac plug | 2,350 (23%) |
| Amulet | 1,787(18%) |
| Amplatzer cardiac plug /amulet | 1,285 (13%) |
| Procedural success | 9,801 (97%) |
| Antithrombotic therapy at discharge | |
| Oral anticoagulant | 1,805 (18%) |
| Warfarin | 717 (40%) |
| Nonvitamin K antagonist oral anticoagulant | 450 (25%) |
| Not specified (Warfarin/NOAC) | 638 (35%) |
| Antiplatelet | 6,942 (69%) |
| Dual antiplatlets | 4,955 (71%) |
| Single antiplatelet | 1,091 (16%) |
| Not specified (SAPT/DAPT) | 896 (13%) |
| Not reported/none/other | 1,317(13%) |
DAPT = dual anti-platelet therapy; NOAC = nonvitamin K antagonist oral anticoagulant; SAPT = single anti-platelet therapy.